Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Seeking Alpha Publishes Article Featuring Advaxis, Inc. (ADXS) 0 comments
    Mar 27, 2013 5:29 PM | about stocks: ADXS

    Advaxis is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to fight off cancer and disease.

    Earlier this week, Seeking Alpha published the following article featuring Advaxis: seekingalpha.com/article/1298241

    The article titled "Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind" provides an overview of the pharmaceutical industry and its challenges. Strong competition from generic drug companies are pressuring Big Pharma to produce a new pipeline of drugs, either through research & development or acquisitions. Based on activity in the market as the pharmaceutical industry moves beyond the hollow specter of the patent cliff, there is a definite interest in buying up companies with promising efforts.

    Jonathan Yates, author of the article, wrote, "Advaxis has more than 15 constructs in various stages of development that are not only distinct, but many are in strategic collaborations with such heavyweights as the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institute, and others . . . Advaxis' lead construct, ADXS-HPV, was honored as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards."

    While honors and awards light up a press release, investors only care about the glow from the bottom line. For the global market for immunotherapies from companies such as Advaxis and Dendreon, sales are estimated to be about $40 billion.

    For more information, visit advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.